Intervention
Tamoxifen
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 140 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownTamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast CancerNCT06434064 · 2026-03-03
RECRUITINGLow Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk ReductionNCT06195306 · 2025-07-28
RECRUITINGAssessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After SurgeryNCT06348134 · 2025-03-18
RECRUITINGAcolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast CancerNCT05941520 · 2024-10-10
RECRUITINGA Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceNCT06492616 · 2024-09-27
RECRUITINGFinding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE TrialNCT06184750 · 2024-09-27
RECRUITINGFunctional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerNCT06179303 · 2024-07-22
RECRUITINGDCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentNCT06075953 · 2024-02-17
RECRUITINGElacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)NCT05512364 · 2023-12-15
RECRUITINGETHAN - ET for Male BCNCT05501704 · 2023-10-11
RECRUITINGEfficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)NCT05891093 · 2023-06-01
RECRUITINGFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsNCT05768139 · 2023-04-17
RECRUITINGA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31
RECRUITINGA Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerNCT04985266 · 2022-03-30
RECRUITINGA Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)NCT05035836 · 2021-11-16
RECRUITINGFES Imaging to Optimize Tamoxifen for Metastatic Breast CancerNCT04174352 · 2020-10-20
RECRUITINGEndocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScoreNCT02476786 · 2017-01-17
RECRUITINGFertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors TrialNCT03011684 · 2016-07-21
RECRUITINGRandomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast CancerNCT07499999 · 2026-09-09
NOT_YET_RECRUITINGSHORTened Duration of TAMoxifenNCT07806630 · 2026-09-01
ACTIVE_NOT_RECRUITINGClinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer PatientsNCT07535905 · 2026-07-01
NOT_YET_RECRUITINGA Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic CancerNCT06630325 · 2025-06-24
TERMINATEDOptimizing Extended Adjuvant Endocrine Therapy in Patients With Breast CancerNCT06223698 · 2025-05-02
NOT_YET_RECRUITINGTesting Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19
SUSPENDEDA Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone TherapyNCT06440967 · 2024-07-31
ACTIVE_NOT_RECRUITINGBreast Cancer & Antiestrogenic Therapy & BrainNCT06346457 · 2024-04-01
UNKNOWNAn Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)NCT05952557 · 2023-10-05
ACTIVE_NOT_RECRUITINGTRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast CancerNCT06001762 · 2023-10-05
ACTIVE_NOT_RECRUITINGPreoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%NCT05659563 · 2023-07-20
COMPLETEDComparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World StudyNCT05801705 · 2023-06-01
UNKNOWNUmbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast CancerNCT05101564 · 2023-03-20
COMPLETEDSafety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA StudyNCT05645536 · 2022-12-28
ENROLLING_BY_INVITATIONTamoxifen Prediction Study in Patients With ER+ Breast CancerNCT05525481 · 2022-11-01
UNKNOWNA Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerNCT05514054 · 2022-10-04
ACTIVE_NOT_RECRUITINGA Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)NCT05306340 · 2022-08-03
ACTIVE_NOT_RECRUITINGRoll-over Study to Allow Continued Access to RibociclibNCT05161195 · 2022-07-07
ACTIVE_NOT_RECRUITINGNeoadjuvant Treatment of Breast CancerNCT05131893 · 2022-03-01
NOT_YET_RECRUITINGNeoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast CancerNCT05150652 · 2022-02-18
COMPLETEDStudy of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related ToxicityNCT05128773 · 2022-02-17
TERMINATEDInvestigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.NCT05016349 · 2021-08-01
UNKNOWNOral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer RiskNCT04570956 · 2021-07-26
TERMINATEDOvarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast CancerNCT04906395 · 2021-07-01
ACTIVE_NOT_RECRUITINGPembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast CancerNCT04190056 · 2021-03-11
TERMINATEDCYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian PopulationNCT05501158 · 2021-01-01
UNKNOWNAnalysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.NCT04852081 · 2021-01-01
UNKNOWNDose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376NCT04961632 · 2020-12-23
UNKNOWNStudy to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC PatientsNCT04300790 · 2020-10-23
COMPLETEDStudy of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast CancerNCT04504331 · 2020-10-13
TERMINATEDEffect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the BreastNCT04666805 · 2020-07-01
UNKNOWNT-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast CancerNCT03554044 · 2020-02-05
COMPLETEDAssessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast CancerNCT03879577 · 2019-11-25
ACTIVE_NOT_RECRUITINGPhase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast CancerNCT04059484 · 2019-10-22
TERMINATEDRadiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone MetastasisNCT03691493 · 2019-02-08
COMPLETEDAssessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast CancerNCT03058939 · 2018-11-01
WITHDRAWNTamoxifen Therapy to Treat Pulmonary Arterial HypertensionNCT03528902 · 2018-10-01
COMPLETEDAnalgesic Efficacy of Pulsed Radiofrequency in Non-cyclic MastalgiaNCT03715413 · 2018-08-15
COMPLETEDA Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）NCT03137368 · 2018-08-09
UNKNOWNSelective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase InhibitorsNCT03382834 · 2018-04-26
COMPLETEDTreatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus PalbociclibNCT02913430 · 2018-04-24
COMPLETEDPAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studYNCT03423199 · 2018-02-09
UNKNOWNCommon conditions
Breast Cancer70Breast Neoplasms14Metastatic Breast Cancer7Anatomic Stage IV Breast Cancer AJCC v86Breast Carcinoma6Breast Lobular Carcinoma in Situ5HER2-negative Breast Cancer5Anatomic Stage III Breast Cancer AJCC v84Breast Cancer Female4Breast Ductal Carcinoma In Situ4Breast Atypical Hyperplasia3Estrogen Receptor Positive Breast Cancer3Prognostic Stage IV Breast Cancer AJCC v83Prostate Cancer3Breast Atypical Lobular Hyperplasia2Breast Cancer Stage II2Breast Cancer Stage III2Breast Cancer, Early Breast Cancer2CYP2D6 Polymorphism2Early-stage Breast Cancer2ER Positive Breast Cancer2ER+ Breast Cancer2Estrogen Receptor Positive2Estrogen Receptor-Positive Breast Carcinoma2HER2-positive Breast Cancer2
Leading sponsors
AstraZeneca
14
University of California, San Francisco
5
Dana-Farber Cancer Institute
4
Eli Lilly and Company
4
Novartis Pharmaceuticals
4
MedSIR
3
National Cancer Institute (NCI)
3
University of Chicago
3
Alliance for Clinical Trials in Oncology
2
ETOP IBCSG Partners Foundation
2
Icahn School of Medicine at Mount Sinai
2
International Breast Cancer Research Foundation
2
Jennifer Lee Caswell-Jin
2
NSABP Foundation Inc
2
Roswell Park Cancer Institute
2
Trial status mix
COMPLETED64
UNKNOWN22
RECRUITING18
ACTIVE_NOT_RECRUITING14
TERMINATED14
NOT_YET_RECRUITING4
SUSPENDED2
ENROLLING_BY_INVITATION1
WITHDRAWN1
Phase mix
PHASE266
PHASE346
PHASE111
NA6
PHASE45
EARLY_PHASE12
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.